Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response Zeuzem S; Rizzetto M; Ferenci P; Shiffman MLAntivir Ther 2009[]; 14 (2): 143-54Current guidelines recommend a full 24-week regimen for all patients undergoing treatment for genotype 2 or 3 hepatitis C virus (HCV) infection. Recent data from two large randomized studies, one with pegylated interferon-alpha2a plus ribavirin (RBV) and one with pegylated interferon-alpha2b plus RBV assessed treatment duration and on-treatment predictors, such as rapid virological response (RVR; HCV RNA <50 IU/ml at week 4) or sustained virological response rates. Overall, these studies have shown that abbreviated regimens are generally less effective than standard 24-week regimens in genotype 2 or 3 patients because of a higher rate of relapse. However, abbreviated treatment might be offered to selected patients with an RVR provided that they have a low baseline viral load and minimal hepatic fibrosis.|*Hepacivirus/drug effects/genetics[MESH]|Antiviral Agents/*administration & dosage[MESH]|Drug Administration Schedule[MESH]|Drug Therapy, Combination[MESH]|Hepatitis C, Chronic/*drug therapy/prevention & control/*virology[MESH]|Humans[MESH]|Interferon alpha-2[MESH]|Interferon-alpha/administration & dosage[MESH]|Polyethylene Glycols/administration & dosage[MESH]|Randomized Controlled Trials as Topic[MESH]|Recombinant Proteins[MESH]|Recurrence[MESH]|Ribavirin/administration & dosage[MESH]|Treatment Outcome[MESH]|Viral Load[MESH] |